Log in

NASDAQ:ACER - Acer Therapeutics Stock Price, Forecast & News

$1.85
-0.36 (-16.29 %)
(As of 03/29/2020 01:34 PM ET)
Today's Range
$1.81
Now: $1.85
$2.24
50-Day Range
$1.18
MA: $3.57
$5.86
52-Week Range
$1.08
Now: $1.85
$28.25
Volume96,560 shs
Average Volume102,586 shs
Market Capitalization$18.69 million
P/E RatioN/A
Dividend YieldN/A
Beta1.61
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of various neuroendocrine disorders. The company was founded in 2013 and is headquartered in Newton, Massachusetts.
Read More
Acer Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACER
CUSIPN/A
Phone844-902-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.82 per share

Profitability

Net Income$-29,420,000.00

Miscellaneous

Employees23
Market Cap$18.69 million
Next Earnings Date5/12/2020 (Estimated)
OptionableNot Optionable

Receive ACER News and Ratings via Email

Sign-up to receive the latest news and ratings for ACER and its competitors with MarketBeat's FREE daily newsletter.


Acer Therapeutics (NASDAQ:ACER) Frequently Asked Questions

How has Acer Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Acer Therapeutics' stock was trading at $3.38 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ACER stock has decreased by 45.3% and is now trading at $1.85. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Acer Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Acer Therapeutics.

When is Acer Therapeutics' next earnings date?

Acer Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 12th 2020. View our earnings forecast for Acer Therapeutics.

How were Acer Therapeutics' earnings last quarter?

Acer Therapeutics Inc (NASDAQ:ACER) announced its earnings results on Wednesday, March, 18th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.48) by $0.03. View Acer Therapeutics' earnings history.

What price target have analysts set for ACER?

5 brokerages have issued 1 year price targets for Acer Therapeutics' stock. Their forecasts range from $9.00 to $48.00. On average, they expect Acer Therapeutics' stock price to reach $22.33 in the next twelve months. This suggests a possible upside of 1,107.2% from the stock's current price. View analysts' price targets for Acer Therapeutics.

Has Acer Therapeutics been receiving favorable news coverage?

Media coverage about ACER stock has been trending extremely negative this week, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Acer Therapeutics earned a daily sentiment score of -4.0 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutAcer Therapeutics.

Who are some of Acer Therapeutics' key competitors?

What other stocks do shareholders of Acer Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acer Therapeutics investors own include Sarepta Therapeutics (SRPT), Amarin (AMRN), Advanced Micro Devices (AMD), Novavax (NVAX), NVIDIA (NVDA), Synergy Pharmaceuticals (SGYP), NovaBay Pharmaceuticals (NBY), Anavex Life Sciences (AVXL), Arena Pharmaceuticals (ARNA) and Exelixis (EXEL).

Who are Acer Therapeutics' key executives?

Acer Therapeutics' management team includes the following people:
  • Mr. Christopher Schelling, Founder, Pres, CEO & Director (Age 43)
  • Mr. Harry S. Palmin, COO & CFO (Age 49)
  • Dr. William T. Andrews M.D., FACP, Chief Medical Officer (Age 54)
  • Mr. Donald R. Joseph, Chief Legal Officer & Sec. (Age 65)
  • Ms. Jeannie Kim, VP of Corp. Devel.

What is Acer Therapeutics' stock symbol?

Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

Who are Acer Therapeutics' major shareholders?

Acer Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include State Street Corp (1.10%), Barclays PLC (0.97%), J. Goldman & Co LP (0.73%), Goldman Sachs Group Inc. (0.51%), Bank of Montreal Can (0.14%) and CWS Financial Advisors LLC (0.10%). Company insiders that own Acer Therapeutics stock include Life Science Ventures Vii Tvm and Steve Aselage. View institutional ownership trends for Acer Therapeutics.

Which major investors are selling Acer Therapeutics stock?

ACER stock was sold by a variety of institutional investors in the last quarter, including J. Goldman & Co LP, Goldman Sachs Group Inc., State Street Corp, and Bank of Montreal Can. View insider buying and selling activity for Acer Therapeutics.

Which major investors are buying Acer Therapeutics stock?

ACER stock was purchased by a variety of institutional investors in the last quarter, including CWS Financial Advisors LLC, UBS Group AG, and Barclays PLC. Company insiders that have bought Acer Therapeutics stock in the last two years include Life Science Ventures Vii Tvm, and Steve Aselage. View insider buying and selling activity for Acer Therapeutics.

How do I buy shares of Acer Therapeutics?

Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Acer Therapeutics' stock price today?

One share of ACER stock can currently be purchased for approximately $1.85.

How big of a company is Acer Therapeutics?

Acer Therapeutics has a market capitalization of $18.69 million. The biopharmaceutical company earns $-29,420,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis. Acer Therapeutics employs 23 workers across the globe. View additional information about Acer Therapeutics.

What is Acer Therapeutics' official website?

The official website for Acer Therapeutics is http://www.acertx.com/.

How can I contact Acer Therapeutics?

Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]


MarketBeat Community Rating for Acer Therapeutics (NASDAQ ACER)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  263 (Vote Outperform)
Underperform Votes:  227 (Vote Underperform)
Total Votes:  490
MarketBeat's community ratings are surveys of what our community members think about Acer Therapeutics and other stocks. Vote "Outperform" if you believe ACER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACER will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel